AstronauTx is a biotechnology company developing small-molecule drugs for the treatment of Alzheimer's disease. The company raised £48M ($61M) in Series A financing to advance its programmes. It intends to use the funds to progress its portfolio, including a clinical study in patients with Alzheimer's for its lead programme. AstronauTx was created in 2019 by Dr Ruth McKernan and Dr David Reynolds and is based in London, UK. In July 2023 it partnered with Danish biotech Saniona to identify new treatments by modulating a novel ion channel target, expanding its pipeline. In September 2023 the company was awarded an Innovate UK grant to fund preclinical work on one of its programmes.

Total raised

$59M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2023